Labels for over-the-counter medicines will soon be easier to read as a result of a new FDA regulation.
Labels for over-the-counter medicines will soon be easier to read as a result of a new Food and Drug Administration regulation, announced Vice President Al Gore and the secretary of the Department of Health and Human Services Donna Shalala.
The new labels, which pharmaceutical manufacturers will have to adopt within six years, must follow a standardized format that clearly shows dosage, ingredients and warnings (see example at left).
"All medicines have benefits and side effects," said Jane Henney, M.D., the commissioner of the Food and Drug Administration. "The improved label will make it easier for patients and consumers to select the appropriate over-the-counter product, and it will help them use that product more effectively."
The new labeling standards, titled "Drug Facts," will require active ingredients to be listed at the top, followed by uses, warnings, directions and inactive ingredients. The Food and Drug Administration has also recommended that manufacturers list their phone numbers on the labels so that consumers can call if they have questions.
Reflecting an awareness of an aging population, the new labeling will also require larger type sizes and other graphic features to improve readability.
Americans can expect to see the first new labels on products within two years, according to the agency. PR
What Every Pharma CEO Should Know About Unlocking the Potential of Scientific Data
December 11th 2024When integrated into pharmaceutical enterprises, scientific data has the potential to drive organizational growth and innovation. Mikael Hagstroem, CEO at leading laboratory informatics provider LabVantage Solutions, discusses how technology partners add significant value to pharmaceutical R&D, in addition to manufacturing quality.
Key Findings of the NIAGARA and HIMALAYA Trials
November 8th 2024In this episode of the Pharmaceutical Executive podcast, Shubh Goel, head of immuno-oncology, gastrointestinal tumors, US oncology business unit, AstraZeneca, discusses the findings of the NIAGARA trial in bladder cancer and the significance of the five-year overall survival data from the HIMALAYA trial, particularly the long-term efficacy of the STRIDE regimen for unresectable liver cancer.